One of the top3 oncology NGS clinical test and diagnosis service provider in China

20+

20+ products and patient care programs, covering all solid tumors

800+

800+ hospitals
with business coverage

40,000+

40,000+patients
we served each year

3DMed Clinical Laboratory

3DMed clinical laboratory was established in October 2015, mainly focusing on molecular diagnostic in terms of laboratory developed test (LDT) business. Since its establishment, the laboratory has always adhered to the principle of quality first, and established a laboratory quality management system in accordance with international standards such as the College of American Pathologists (CAP) and ISO15189. Since 2016, it has passed the external quality assessment(EQA)of international ( CAP and EMQN) and domestic (National Health Commission and Shanghai Center for Clinical laboratory) for 50 consecutive times

The laboratory passed the CAP on-site review on December 7, 2017, and passed the CLIA certification on May 22, 2019, which indicates that the quality system and the reports issued by 3DMed clinical laboratory have been recognized globally.

Medical Laboratory Qualification

3DMed’rigorous multi-tier quality control system ensures accuracy and timeliness of testing
· 3DMed Clinical Laboratory is one of the few high-standard laboratories in China that conduct pathological quality control. By stringent QC systems, we examine the pathological type of tumors, guarantee enough tumor cell amounts and avoid interference from necrotic cells, thus ensuring accurate test results.

· The only diagnostic laboratory that has cell line standards and can collaborate with hospitals to develop an external quality assessment.

· The only China-based clinical laboratory that has passed NGS external quality assessments from both China and America on tumor germline, solid tumor tissue and ctDNA.

· The only contributor of NGS detection parameters in China's first NGS diagnostic consensus.

Top scientific achievements

Association of high tumor mutation (TMB) with DNA damage repair (DDR) alterations and better prognosis in ovarian cancer.